Catégorie : Essais Cliniques

Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment, Tibor Stark, 2020,

Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment Tibor Stark, Martina Di Bartolomeo, Roberta Di Marco, Eva Drazanova, Chiara Bianca Maria Platania, Fabio Arturo Iannotti, Jana Ruda-Kucerova, Claudio D'Addario, Lucie Kratka, Vladimir Pekarik, Fabiana Piscitelli, Zuzana Babinska, Julia Fedotova, Giovanni Giurdanella, Salvatore Salomone, Alexandra Sulcova, Claudio Bucolo, Carsten T.Wotjak, Zenon Starcuk Jr, Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo, Vincenzo Micale Biochemical Pharmacology, April 2020, 1-12. doi : 10.1016/j.bcp.2020.114004     Un excellent article international (République Tchèque, Allemagne, Italy, Russie, Israel, Canada), avec la plus grande plume de la recherche sur les cannabinoïdes (Mechoulam, Di Marzo...) qui [...]

Lire la suite

In Search of Preventative Strategies: Novel Anti- Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues, Bo Wang et al., 2020

In Search of Preventative Strategies: Novel Anti- Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues Bo Wang, Anna Kovalchuk, Dongping Li, Yaroslav Ilnytskyy, Igor Kovalchuk and Olga Kovalchuk Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 19 April 2020 doi : 10.20944/preprints202004.0315.v1   Abstract : With the rapidly growing pandemic of COVID-19 caused by the new and challenging to treat zoonotic SARS-CoV2 coronavirus, there is an urgent need for new therapies and prevention strategies that can help curtail disease spread and reduce mortality. Inhibition of viral entry and thereby spread constitute plausible therapeutic avenues. Similar to other respiratory pathogens, SARS-CoV2 is transmitted [...]

Lire la suite

Rationale for cannabis-based interventions in the opioid overdose crisis, Philippe Lucas, 2017

Rationale for cannabis-based interventions in the opioid overdose crisis Philippe Lucas Harm Reduction Journal, 2017, 14, 58 Doi : 10.1186/s12954-017-0183-9   Abstract Background : North America is currently in the grips of a crisis rooted in the use of licit and illicit opioid-based analgesics. Drug overdose is the leading cause of accidental death in Canada and the US, and the growing toll of opioid-related morbidity and mortality requires a diversity of novel therapeutic and harm reduction-based interventions. Research suggests that increasing adult access to both medical and recreational cannabis has significant positive impacts on public health and safety as a result of substitution effect. Observational and [...]

Lire la suite

Potential combinations of endocannabinoid/endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus, Mark Feldman et al., 2020

Potential combinations of endocannabinoid/endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus Mark Feldman, Reem Smoum, Raphael Mechoulam, Doron Steinberg PLoS One, April 15, 2020, 1-13. Doi : 10.1371/journal.pone.0231583   Abstract Infections caused by antibiotic-resistant strains of Staphylococcus aureus have reached epidemic proportions globally. Our previous study showed antimicrobial effects of anandamide (AEA) and arachidonoyl serine (AraS) against methicillin (MET)-resistant S. aureus (MRSA) strains, proposing the therapeutic potential of these endocannabinoid/endocannabinoid-like (EC/EC-like) agents for the treatment of MRSA. Here, we investigated the potential synergism of combinations of AEA and AraS with different types of antibiotics against MRSA grown under planktonic growth or biofilm formation. The most effective [...]

Lire la suite

Cannabis Use Patterns and Motives: A Comparison of Younger, Middle-Aged, and Older Medical Cannabis Dispensary Patients, Nancy A. Haug et al., 2017

Cannabis Use Patterns and Motives: A Comparison of Younger, Middle-Aged, and Older Medical Cannabis Dispensary Patients Nancy A. Haug, Claudia B. Padula, James E. Sottile, Ryan Vandrey, Adrienne J. Heinz, and Marcel O. Bonn-Miller Addictive Behaviors, 2017, 72, 14-20. Doi : 10.1016/j.addbeh.2017.03.006   Abstract Introduction : Medical cannabis is increasingly being used for a variety of health conditions as more states implement legislation permitting medical use of cannabis. Little is known about medical cannabis use patterns and motives among adults across the lifespan. Methods : The present study examined data collected at a medical cannabis dispensary in San Francisco, California. Participants included 217 medical cannabis patients who [...]

Lire la suite

Un hôpital commence à traiter les patients du COVID-19 avec le cannabis, Times of Israel . com, 2020

Un hôpital commence à traiter les patients du COVID-19 avec le cannabis   https://fr.timesofisrael.com/liveblog_entry/un-hopital-commence-a-traiter-les-patients-du-covid-19-avec-le-cannabis/ L’hôpital Ichilov a commencé à administrer du cannabis médicinal aux patients atteints du coronavirus en état modéré dans le cadre d’un traitement expérimental, a rapporté la Douzième chaîne. Les docteurs cherchent à utiliser les propriétés antivirales du cannabis pour ralentir la propagation du virus, a annoncé l’hôpital.

Lire la suite

The Broad Concept of “Spasticity- Plus Syndrome” in Multiple Sclerosisv: A Possible New Concept in the Management of Multiple Sclerosis Symptoms, Óscar Fernández et al., 2020

The Broad Concept of “Spasticity- Plus Syndrome” in Multiple Sclerosis : A Possible New Concept in the Management of Multiple Sclerosis Symptoms Óscar Fernández, Lucienne Costa-Frossard, Marisa Martínez-Ginés, Paloma Montero, José Maria Prieto and Lluis Ramió Frontiers in Neurology , 2020 | Volume 11 | Article 152 doi : 10.3389/fneur.2020.00152   Multiple sclerosis (MS) pathology progressively affects multiple central nervous system (CNS) areas. Due to this fact, MS produces a wide array of symptoms. Symptomatic therapy of one MS symptom can cause or worsen other unwanted symptoms (anticholinergics used for bladder dysfunction produce impairment of cognition, many MS drugs produce erectile dysfunction, etc.). Appropriate symptomatic [...]

Lire la suite

Cannabinol inhibits proliferation and induces cell cycle arrest and apoptosis in glioblastoma, hepatocellular carcinoma and breast cancer cells, Nuanying Zhong, 2020

Cannabinol inhibits proliferation and induces cell cycle arrest and apoptosis in glioblastoma, hepatocellular carcinoma and breast cancer cells Nuanying ZHONG, Thesis, Master of Science in Biological Sciences Faculty of Arts and Science, Department of Biological Sciences, University of Lethbridge Research Repository, Canada 2020 https://hdl.handle.net/10133/5697   ABSTRACT Cannabis sativa is an agriculturally and medicinally plant with many pharmaceutical properties. Cancer is a deadly disease; it is estimated that it will cause over 80 thousand deaths in 2019 in Canada. Although numerous studies have demonstrated that cannabinoids have anti-tumorous properties in various cancers, the anti-malignant activities of cannabinol (CBN) on carcinogenesis and underlying mechanisms remain largely unknown. In this study, we [...]

Lire la suite

CBD Reverts the Mesenchymal Invasive Phenotype of Breast Cancer Cells Induced by the Inflammatory Cytokine IL-1, Lázaro García-Morales et al., 2020

CBD Reverts the Mesenchymal Invasive Phenotype of Breast Cancer Cells Induced by the Inflammatory Cytokine IL-1 Lázaro García-Morales, Aída M Castillo, José Tapia Ramírez, Horacio Zamudio-Meza, Ma del Carmen Domínguez-Robles and Isaura Meza International Journal of Molecular Science, 2020, 21, 2429 doi : 10.3390/ijms21072429   Abstract : Cannabidiol (CBD) has been used to treat a variety of cancers and inflammatory conditions with controversial results. In previous work, we have shown that breast cancer MCF-7 cells, selected by their response to inflammatory IL-1 cytokine, acquire a malignant phenotype (6D cells) through an epithelial mesenchymal transition (EMT).We evaluated CBD as a potential inhibitor of this transition and inducer of [...]

Lire la suite

High Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity, Marie Fitzgibbon et al., 2016

High Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity Marie Fitzgibbon, David P. Finn,  Michelle Roche International Journal of Neuropsychopharmacology, 2016, 19, (3), 1–20 doi : 10.1093/ijnp/pyv095   Abstract Depression and pain are two of the most debilitating disorders worldwide and have an estimate co-occurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired healthrelated quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation [...]

Lire la suite